BiotechTube

13-valent pneumococcal conjugate vaccine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

13-valent Pneumococcal Vaccine

Conditions

13-valent Pneumococcal Vaccine, Immunization, Safety, Antibody Response

Trial Timeline

Apr 1, 2010 → Nov 1, 2010

NCT ID
NCT01026038

About 13-valent pneumococcal conjugate vaccine

13-valent pneumococcal conjugate vaccine is a phase 3 stage product being developed by Pfizer for 13-valent Pneumococcal Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT01026038. Target conditions include 13-valent Pneumococcal Vaccine, Immunization, Safety.

What happened to similar drugs?

1 of 1 similar drugs in 13-valent Pneumococcal Vaccine were approved

Approved (1) Terminated (0) Active (0)
✅13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT05329259ApprovedCompleted
NCT03571607Phase 3Completed
NCT02034877ApprovedCompleted
NCT01026038Phase 3Completed
NCT00963235Phase 3Completed
NCT00708682Phase 3Completed
NCT00500357Phase 3Completed
NCT00452452Phase 3Completed
NCT00464945Phase 3Completed
NCT00269672Phase 2Completed

Competing Products

1 competing product in 13-valent Pneumococcal Vaccine

See all competitors
ProductCompanyStageHype Score
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccinePfizerApproved
43